BR112015000940A2 - composto, composição farmacêutica, métodos para tratar um distúrbio, para acelerar o reparo e cura da fratura da bacia, e para acelerar o aquecimento de queima e, uso de um composto - Google Patents

composto, composição farmacêutica, métodos para tratar um distúrbio, para acelerar o reparo e cura da fratura da bacia, e para acelerar o aquecimento de queima e, uso de um composto

Info

Publication number
BR112015000940A2
BR112015000940A2 BR112015000940A BR112015000940A BR112015000940A2 BR 112015000940 A2 BR112015000940 A2 BR 112015000940A2 BR 112015000940 A BR112015000940 A BR 112015000940A BR 112015000940 A BR112015000940 A BR 112015000940A BR 112015000940 A2 BR112015000940 A2 BR 112015000940A2
Authority
BR
Brazil
Prior art keywords
compound
accelerate
methods
healing
disorder
Prior art date
Application number
BR112015000940A
Other languages
English (en)
Other versions
BR112015000940B1 (pt
Inventor
Stewart Turnbull Philip
Cadilla Rodolfo
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015000940(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of BR112015000940A2 publication Critical patent/BR112015000940A2/pt
Publication of BR112015000940B1 publication Critical patent/BR112015000940B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

1 / 1 resumo “composto, composiã‡ãƒo farmacãšutica, mã‰todos para tratar um distãšrbio, para acelerar o reparo e cura da fratura da bacia, e para acelerar o aquecimento de queima e, uso de um composto” esta invenã§ã£o refere-se aos compostos nã£o esteroidais que sã£o moduladores do receptor de andrã³geno, e tambã©m aos mã©todos para a fabricaã§ã£o e uso de tais compostos.
BR112015000940-9A 2012-07-17 2013-07-15 Composto, composição farmacêutica, e, uso de um composto BR112015000940B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261672455P 2012-07-17 2012-07-17
US61/672,455 2012-07-17
US201361748874P 2013-01-04 2013-01-04
US61/748,874 2013-01-04
PCT/IB2013/001530 WO2014013309A1 (en) 2012-07-17 2013-07-15 Indolecarbonitriles as selective androgen receptor modulators

Publications (2)

Publication Number Publication Date
BR112015000940A2 true BR112015000940A2 (pt) 2017-06-27
BR112015000940B1 BR112015000940B1 (pt) 2022-05-17

Family

ID=49117887

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015000940-9A BR112015000940B1 (pt) 2012-07-17 2013-07-15 Composto, composição farmacêutica, e, uso de um composto

Country Status (39)

Country Link
US (5) US8957104B2 (pt)
EP (1) EP2875013B1 (pt)
JP (1) JP6106746B2 (pt)
KR (1) KR102127939B1 (pt)
CN (1) CN104619693B (pt)
AR (1) AR091770A1 (pt)
AU (1) AU2013291721B2 (pt)
BR (1) BR112015000940B1 (pt)
CA (1) CA2879104C (pt)
CL (1) CL2015000119A1 (pt)
CO (1) CO7240378A2 (pt)
CR (1) CR20150008A (pt)
CY (1) CY1120064T1 (pt)
DK (1) DK2875013T3 (pt)
DO (1) DOP2015000004A (pt)
EA (1) EA026371B8 (pt)
ES (1) ES2657912T3 (pt)
HK (1) HK1208867A1 (pt)
HR (1) HRP20180061T1 (pt)
HU (1) HUE036238T2 (pt)
IL (1) IL236448A (pt)
IN (1) IN2014KN02993A (pt)
JO (1) JO3384B1 (pt)
LT (1) LT2875013T (pt)
ME (1) ME02996B (pt)
MX (1) MX349943B (pt)
MY (2) MY173845A (pt)
NZ (1) NZ703129A (pt)
PE (1) PE20150371A1 (pt)
PH (1) PH12015500104B1 (pt)
PL (1) PL2875013T3 (pt)
PT (1) PT2875013T (pt)
RS (1) RS56810B1 (pt)
SG (1) SG11201408493WA (pt)
SI (1) SI2875013T1 (pt)
TW (1) TWI574946B (pt)
UY (1) UY34911A (pt)
WO (1) WO2014013309A1 (pt)
ZA (1) ZA201500096B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
JP6106746B2 (ja) 2012-07-17 2017-04-05 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 選択的アンドロゲン受容体調節剤としてのインドールカルボニトリル類
WO2015110958A1 (en) 2014-01-21 2015-07-30 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile
EP3206675A4 (en) * 2014-10-16 2018-07-11 GTx, Inc. METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs
CN105130872B (zh) * 2015-08-25 2018-01-30 江西师范大学 一种3位三氟甲基取代吲哚的制备方法
CN110437125B (zh) * 2019-09-06 2021-03-12 苏州旺山旺水生物医药有限公司 一种Tezacaftor中间体II的制备方法
WO2022204235A1 (en) * 2021-03-23 2022-09-29 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
CN115010574B (zh) * 2022-06-06 2024-01-05 爱斯特（成都）生物制药股份有限公司 1-溴-2-氯-4-氟-2碘苯的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1056719A2 (en) 1998-02-25 2000-12-06 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
ID26698A (id) * 1998-06-19 2001-02-01 Pfizer Prod Inc SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
US7235668B2 (en) 2002-05-24 2007-06-26 Bayer Cropscience Ag Process for the preparation of thioalkylamine derivatives
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
CN1960973A (zh) * 2004-03-30 2007-05-09 惠氏公司 作为去甲肾上腺素(ne)与血清素(5－h t)活性和单胺重摄取的调控剂以治疗血管舒缩症状(vms)的1－(1h－吲哚－1－基)－3－(4－甲基哌嗪－1－基)－1－苯基丙烷－2－醇衍生物和相关化合物
ATE525354T1 (de) 2004-05-03 2011-10-15 Janssen Pharmaceutica Nv Benzofuranderivate als selektive androgenrezeptormodulatoren (sarms)
US7427682B2 (en) 2004-05-03 2008-09-23 Janssen Pharmaceutica N.V. Indole derivatives as selective androgen receptor modulators (SARMS)
EP1753749B1 (en) 2004-05-03 2014-07-30 Janssen Pharmaceutica NV Novel indole derivatives as selective androgen receptor modulators (sarms)
EP1756054B1 (en) * 2004-06-01 2010-03-31 F.Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor
EP1913000B1 (en) * 2005-07-29 2012-01-11 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CN101426778A (zh) * 2006-03-15 2009-05-06 惠氏公司 作为组胺-3拮抗剂的n-经取代-氮杂环基胺
CA2645731A1 (en) * 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
EP2079466B1 (en) * 2006-09-29 2014-01-15 GlaxoSmithKline LLC Substituted indole compounds
JP4884570B2 (ja) * 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
WO2010118287A1 (en) * 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
IN2012DN02577A (pt) * 2009-10-15 2015-08-28 Pfizer
JP5739446B2 (ja) * 2009-12-18 2015-06-24 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
DK2590647T3 (en) 2010-07-07 2018-02-12 Univ Texas Pro-neurogenic compounds
US8933113B2 (en) * 2011-01-20 2015-01-13 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
PL2796460T3 (pl) * 2011-12-21 2018-12-31 Jiangsu Hengrui Medicine Co. Ltd. Sześcioczłonowa pirolowa heteroarylowa pochodna pierścieniowa, sposób jej otrzymywania i zastosowania medyczne
JP6106746B2 (ja) * 2012-07-17 2017-04-05 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 選択的アンドロゲン受容体調節剤としてのインドールカルボニトリル類
WO2015110958A1 (en) * 2014-01-21 2015-07-30 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile

Also Published As

Publication number Publication date
JP2015522603A (ja) 2015-08-06
ZA201500096B (en) 2017-07-26
HUE036238T2 (hu) 2018-06-28
MX349943B (es) 2017-08-21
EP2875013A1 (en) 2015-05-27
US11299457B2 (en) 2022-04-12
SI2875013T1 (en) 2018-03-30
CY1120064T1 (el) 2018-12-12
US20200270210A1 (en) 2020-08-27
BR112015000940B1 (pt) 2022-05-17
EA026371B1 (ru) 2017-03-31
PE20150371A1 (es) 2015-03-27
IL236448A0 (en) 2015-02-26
US20140024694A1 (en) 2014-01-23
CL2015000119A1 (es) 2015-04-24
CN104619693B (zh) 2019-08-13
DOP2015000004A (es) 2015-03-15
AU2013291721B2 (en) 2016-02-25
CO7240378A2 (es) 2015-04-17
EA201492237A1 (ru) 2015-06-30
US10710963B2 (en) 2020-07-14
KR102127939B1 (ko) 2020-06-29
LT2875013T (lt) 2018-02-26
PH12015500104A1 (en) 2015-03-02
ES2657912T3 (es) 2018-03-07
US8957104B2 (en) 2015-02-17
JP6106746B2 (ja) 2017-04-05
PL2875013T3 (pl) 2018-06-29
JO3384B1 (ar) 2019-03-13
CA2879104A1 (en) 2014-01-23
US20190127326A1 (en) 2019-05-02
US10196353B2 (en) 2019-02-05
UY34911A (es) 2014-02-28
KR20150032333A (ko) 2015-03-25
EA026371B8 (ru) 2017-06-30
US20170073309A1 (en) 2017-03-16
CR20150008A (es) 2015-03-09
IN2014KN02993A (pt) 2015-05-08
WO2014013309A1 (en) 2014-01-23
AU2013291721A1 (en) 2015-02-26
DK2875013T3 (en) 2018-01-22
RS56810B1 (sr) 2018-04-30
AR091770A1 (es) 2015-02-25
MY173845A (en) 2020-02-24
IL236448A (en) 2016-10-31
TWI574946B (zh) 2017-03-21
HK1208867A1 (en) 2016-03-18
US20150080449A1 (en) 2015-03-19
CA2879104C (en) 2020-08-25
ME02996B (me) 2018-10-20
US9533948B2 (en) 2017-01-03
SG11201408493WA (en) 2015-02-27
HRP20180061T1 (hr) 2018-02-23
MY198512A (en) 2023-09-01
PH12015500104B1 (en) 2015-03-02
EP2875013B1 (en) 2017-11-29
CN104619693A (zh) 2015-05-13
NZ703129A (en) 2017-06-30
TW201416349A (zh) 2014-05-01
PT2875013T (pt) 2018-02-28
MX2015000825A (es) 2015-07-17

Similar Documents

Publication Publication Date Title
BR112015000940A2 (pt) composto, composição farmacêutica, métodos para tratar um distúrbio, para acelerar o reparo e cura da fratura da bacia, e para acelerar o aquecimento de queima e, uso de um composto
CL2017003288A1 (es) Métodos para tratar o prevenir enfermedades relacionadas con el colesterol (divisional solicitud 201303214)
CO6551721A2 (es) Moduladores de cinasa novedosos
BR112017020150A2 (pt) materiais compósitos e elementos de ligação oriundos da cabonicação de silicato de cálcio e métodos dos mesmos
CL2015003314A1 (es) Inhibidores de acc y usos de los mismos
CR20110103A (es) Heteroarilos sustituidos
BR112015011147A8 (pt) composto, composição farmacêutica, e, uso do referido composto
CL2015003315A1 (es) Inhibidores de acc y usos de los mismos
BR112015011148A8 (pt) composto, composição farmacêutica, e combinação
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
ECSP088823A (es) Quinazolinas para la inhibición de pdk1
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
BR112014029706A8 (pt) Composto, composição farmacêutica, e, uso de um composto
BR112015024050A2 (pt) composto, composição farmacêutica, e, uso de um composto
GT201400109A (es) Derivados de 6,7-dihidro-5h-benzo(7)anuleno, procesos para su preparación, productos farmacéuticos que comprenden a los mismos y su uso en la preparacion de medicamentos.
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
GT201400090A (es) 2-tiopirimidinonas
HN2009000566A (es) Nuevos derivados de diosmetina, su procedimiento de prearacion y las composiciones farmaceuticas que lo contienen.
CL2008002185A1 (es) Compuestos derivados de pirimidina, inhibidores de fosfatidilinositol-3-cinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades resapiratorias, alergias, inflamacion, cancer, entre otras enfermedades.
BR112018011607A2 (pt) composto, composição farmacêutica, métodos para tratamento de um distúrbio relacionado ao estrogênio e de um câncer, para fabricação de um medicamento para uso terapêutico no tratamento de um distúrbio e para prevenção de um distúrbio relacionado ao estrogênio, uso de um composto ou de uma composição farmacêutica, e, processo para preparação de um produto farmacêutico.
BR112015023891A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112015023858A2 (pt) composto, composição farmacêutica, e, uso de um composto
DOP2012000317A (es) Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
BR112016010072A8 (pt) conjugado, composição farmacêutica, usos do conjugado ou da composição farmacêutica, e de polissacarídeo de vi fragmentado, e, método para a fabricação de um conjugado
BR112015023878A2 (pt) composto, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/07/2013, OBSERVADAS AS CONDICOES LEGAIS